AI Article Synopsis
- Epilepsy impacts nearly 50 million people globally, creating significant financial burdens on both healthcare systems and patients.
- A study in Poland assessed the direct and indirect costs of epilepsy from 2014 to 2018, revealing a decrease in total costs over time, with indirect costs being the most significant contributor.
- Findings showed that while total epilepsy-related costs dropped from EUR 410 million in 2014 to EUR 361 million in 2018, indirect costs accounted for a large portion, mostly due to long-term absenteeism, emphasizing the need for targeted attention from policymakers.
Article Abstract
Introduction: Epilepsy affects nearly 50 million people around the world. As a common and chronic disease generates a high cost burden for healthcare system and patients.
Aim: We aimed to determine the most current direct and indirect costs of epilepsy in Poland from the social perspective for the years 2014-2018, to analyze the changes of expenditures over time, indicate trends and to determine key cost-drivers.
Material And Methods: Direct and indirect costs using a top-down approach were estimated based on the public institutions' data for the ICD-10 codes G40 and G41. Direct costs included pharmacotherapy, hospitalizations, outpatient specialist care and rehabilitation. A human capital approach was used to estimate loss of productivity due to sick leaves and long-term inability to work.
Results: Annual total direct and indirect costs related to epilepsy accounted for EUR 410 million in 2014 and decreased in subsequent years to EUR 361 million in 2018. The indirect costs were dominant (76-83% of total costs) and in the majority related to the long-term absenteeism (87-92% of total indirect costs). In 2014-2018, patients with epilepsy generated EUR 341 million to EUR 282 million of indirect costs. Annual direct costs for patients with epilepsy were EUR 69 million in 2014 and increased to EUR 80 million in 2018. The biggest expenses were the costs of drugs (> 50%) and hospitalizations (~ 40%).
Conclusions: Epilepsy is an expensive disorder in terms of consumption of resources and social costs. Decision-makers should take it under special consideration.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10198-021-01269-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Accurate estimates of incremental cost (IC) attributable to antimicrobial resistance (AMR) provide information of immense public health importance to the policy makers. Here, we present the IC from patient perspective for treating antimicrobial-resistant pathogens in India.
Methods: This cohort study was conducted in eight hospitals including government (GH), private (PH) and trust hospitals (TH), considering their ownership, geographical location and categories of cities.
Economic burden of acute kidney injury in children and adults: a protocol for a systematic review and meta-analysis.
BMJ Open
December 2024
Department of Critical Care Medicine, University of Alberta, Edmonton, Alberta, Canada
Introduction: Acute kidney injury (AKI) is common in hospitalised adults and children and is associated with significantly increased mortality and worse short-term and long-term outcomes. This systematic review and meta-analysis will evaluate the cost associated with AKI.
Methods And Analysis: This health economic analysis will be performed using systematic search of databases, including MEDLINE, EMBASE, CINAHL, Scopus and Cochrane Library from 2009 to the present (search completed on 27 May 2024).
Cost-Utility of Lumbar Interbody Fusion Surgery: A Systematic Review.
Spine J
January 2025
Hoag Orthopedics, 16300 Sand Canyon Ave., Suite. 500, Irvine, CA 92618, United States. Electronic address:
Background Context: Lumbar interbody fusion (LIF) is a common surgical intervention for treating lumbar degenerative disorders. Increasing demand has contributed to ever-increasing healthcare expenditure and economic burden. To address this, cost-utility analyses (CUAs) compare value in the context of patient outcomes.
View Article and Find Full Text PDFAssociation Between Diagnostic Delay and Economic and Clinical Burden in Axial Spondyloarthritis: A Multicentre Retrospective Observational Study.
Rheumatol Ther
January 2025
Rheumatology Department, Parc Taulí University Hospital. Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona, Parc Taulí, 1, Sabadell, 08208, Barcelona, Spain.
Introduction: Axial spondyloarthritis (axSpA) is a chronic inflammatory condition associated with considerable pain and impaired health-related quality of life (HRQoL) for affected patients. Despite the documented increase in healthcare resource utilization (HRU) related to axSpA, few studies have explored the impact of diagnostic delays on these outcomes. This study sought to determine the association between diagnostic delay of axial spondyloarthritis (axSpA) and costs in the 3 years after diagnosis.
View Article and Find Full Text PDFChronic bacterial infections exert metabolic costs in Drosophila melanogaster.
J Exp Biol
January 2025
Department of Entomology, Cornell University, Ithaca, NY 14853, USA.
Bacterial infections can substantially impact host metabolic health as a result of the direct and indirect demands of sustaining an immune response and of nutrient piracy by the pathogen itself. Drosophila melanogaster and other insects that survive a sublethal bacterial infection often carry substantial pathogen burdens for the remainder of life. In this study, we asked whether these chronic infections exact metabolic costs for the host, and how these costs scale with the severity of chronic infection.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!